Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaMarco L. Davila, Renier J. Brentjens, Jinrong Qu et al.|Science Translational Medicine|2014Cited by 2.5k
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALLKevin J. Curran, Renier J. Brentjens|Blood|2019Cited by 277
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cellsHaneen Shalabi, Nirali N. Shah, Juliane Gust et al.|Nature Reviews Clinical Oncology|2021Cited by 68
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell TherapyKai Rejeski, Roni Shouval, Jaime Sanz et al.|Blood|2025Cited by 31